Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
      • Social Behavioral Science Core (SBSC)
    • Funding Acknowledgements
    • Network Sites
    • Staff Spotlights
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Anne Coletti

Email

acoletti@fhi360.org

Phone

(919) 627-6445

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701

Request an Update

Affiliated Studies

P1058A: Pharmacokinetics of New Classes of Antiretroviral Drug Combinations

DAIDS Number

10809

Research Area

Other

Study Status

Concluded

P1080: ARV & Psychiatric Medication Concentrations in HIV Infected & Uninfected Children

DAIDS Number

10768

Research Area

Complications & Comorbidities

Study Status

Closed to Follow Up

P1111: Safety, Tolerability and PK of Rilpivirine

DAIDS Number

11902

Research Area

Antiretroviral Strategies

Study Status

Withdrawn

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

1077BF: PROMISE 1077BF

DAIDS Number

10777

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network